A Randomized, Double-blind, Parallel-group, Placebo-controlled, Single-dose Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Denosumab Injection Administered Subcutaneously to Healthy Adults in China
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2018
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- 08 Feb 2018 Status changed from planning to recruiting.
- 21 Aug 2017 New trial record
- 04 Aug 2017 According to a Luye Pharma media release, LY06006 has been accepted for clinical trials in China.